Could a gentler chemo plus immunotherapy tame advanced lung cancer?
NCT ID NCT05312840
First seen Jun 02, 2026 · Last updated Jun 20, 2026 · Updated 5 times
Summary
This completed Phase 4 trial tested two chemotherapy doses (standard and low) combined with the immunotherapy drug sintilimab in 20 adults with advanced squamous non-small cell lung cancer. The goal was to see how well the treatment shrank tumors and controlled the disease, while also checking safety. The study compared a routine-dose group to a low-dose group, with sintilimab given on day 8 of each 3-week cycle.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Quzhou people's Hospital
Quzhou, Zhejiang, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cisplatin or Carboplatin, Gemcitabine, and Sintilimab
What this could lead to
If successful, this could point toward a less toxic chemotherapy regimen combined with immunotherapy for advanced lung cancer.
What could go wrong
This is a very small, completed Phase 4 trial with only 20 participants, so results may not apply broadly. The combination may still cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.